12:13 PM EDT, 03/19/2026 (MT Newswires) -- Novo Nordisk ( NVO ) said Thursday the US Food and Drug Administration has approved its once-weekly Wegovy HD injection to lower excess body weight and sustain long-term weight loss.

The accelerated approval was supported by late-stage trial data where the 7.2-milligram dose produced an average of 21% weight loss in obese participants, the company said.

A separate trial involving obese patients with type 2 diabetes showed a 14% average weight reduction, the drugmaker added.

Price: 36.83, Change: -0.62, Percent Change: -1.66